Skip to main content
OPTUS Pharmaceutical Co., Ltd. logo

OPTUS Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 131030 ISIN · KR7131030009 KO Manufacturing
Open in API
Filings indexed 159 across all filing types
Latest filing 2024-10-08 Major Shareholding Noti…
Country KR South Korea
Listing KO 131030

About OPTUS Pharmaceutical Co., Ltd.

http://optuspharm.com/us/main/index.php

OPTUS Pharmaceutical Co., Ltd. is a specialized pharmaceutical company focused on the research, development, manufacturing, and commercialization of ophthalmic products. The company's primary expertise lies in producing sterile, preservative-free, single-dose (unit-dose) formulations. Its therapeutic portfolio addresses conditions such as dry eye syndrome, keratoconjunctival epithelial disease, bacterial conjunctivitis, and glaucoma. In addition to prescription and over-the-counter pharmaceuticals, the company is expanding into a total eye care model through its OUE& brand, which encompasses nutritional supplements (OUEFIT) and cosmeceuticals (OUELAB). The company operates EU-GMP certified manufacturing facilities and distributes its products globally.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This specific document reports a change in shareholding percentage (crossing the 5% threshold) by Korea Securities Finance Corp in Optipharm Co., Ltd. In the context of global financial document classification, this corresponds to a 'Major Shareholding Notification' (MRQ).
2024-10-08 Korean
투자판단관련주요경영사항 (노안치료제 신약도입(License Agreement)계약 체결)
M&A Activity Classification · 100% confidence The document is a formal regulatory disclosure from Optipharm (옵투스제약) regarding a 'License Agreement' for a new drug (QLOSI). It details the contract terms, financial obligations (upfront payments and milestones), and strategic implications. In the context of Korean stock exchange filings (DART), this is classified as a 'Major Management Matter' (주요경영사항), which falls under the 'Regulatory Filings' category as it represents a specific corporate event disclosure that does not fit into more specialized categories like M&A or financial reports.
2024-09-23 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '옵투스제약' (Optus Pharmaceuticals) for the period ending June 30, 2024. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-14 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Report' (영업(잠정)실적) for Optus Pharm, detailing quarterly financial highlights such as revenue, operating profit, and net income for the period ending 2024.06.30. It is a standard initial announcement of financial results, which fits the definition of an Earnings Release (ER). Q2 2024
2024-07-25 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (Corporate Day). It provides details such as the date, location, purpose, and contact information for the event. It does not contain the actual presentation slides or financial data, but rather announces the event and the availability of materials on the company website. According to the 'Menu vs Meal' rule, an announcement of an event or report is classified as a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Given this is a notice of an IR event, RNS is the most appropriate classification.
2024-06-19 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Optus Pharmaceuticals' (주)옵투스제약 for the period from January 1, 2024, to March 31, 2024. It contains detailed financial information, business operations, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.